NASDAQ:ORMP - Oramed Pharmaceuticals Stock Price, Forecast & News

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Thursday, January, 9th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.11. The biotechnology company had revenue of $0.67 million for the quarter. Oramed Pharmaceuticals had a negative return on equity of 38.51% and a negative net margin of 297.30%. View Oramed Pharmaceuticals' Earnings History.

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Oramed Pharmaceuticals.

2 equities research analysts have issued 1 year price targets for Oramed Pharmaceuticals' shares. Their forecasts range from $7.00 to $20.00. On average, they expect Oramed Pharmaceuticals' stock price to reach $13.50 in the next year. This suggests a possible upside of 150.9% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.

News stories about ORMP stock have trended negative on Saturday, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a news impact score of -2.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Oramed Pharmaceuticals.

Oramed Pharmaceuticals saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 448,700 shares, a decline of 23.5% from the December 15th total of 586,300 shares. Based on an average trading volume of 210,900 shares, the days-to-cover ratio is currently 2.1 days. Currently, 3.4% of the company's stock are sold short. View Oramed Pharmaceuticals' Current Options Chain.

Some companies that are related to Oramed Pharmaceuticals include Spectrum Pharmaceuticals (SPPI), Recro Pharma (REPH), Syros Pharmaceuticals (SYRS), OptiNose (OPTN), Stemline Therapeutics (STML), Galera Therapeutics (GRTX), CytomX Therapeutics (CTMX), INDIVIOR PLC/S (INVVY), Kalvista Pharmaceuticals (KALV), Minerva Neurosciences (NERV), Albireo Pharma (ALBO), MannKind (MNKD), BioXcel Therapeutics (BTAI), MediciNova (MNOV) and Satsuma Pharmaceuticals (STSA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), Zynerba Pharmaceuticals (ZYNE), Pluristem Therapeutics (PSTI), Caladrius Biosciences (CLBS), Andrea Electronics (ANDR), Micron Technology (MU) and Tonix Pharmaceuticals (TNXP).

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ORMP stock can currently be purchased for approximately $5.38.

Oramed Pharmaceuticals has a market capitalization of $95.42 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis. View Additional Information About Oramed Pharmaceuticals.

The official website for Oramed Pharmaceuticals is http://www.oramed.com/.

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]